Embodiments of the present disclosure provide for -AApeptides, -AApeptide building blocks, methods of making -AApeptides and libraries of -AApeptides, methods of screening the -AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for -AApeptides that are inhibitors of A peptide aggregation, methods of inhibiting and disassembling A peptide aggregation, methods of inhibiting the toxicity of A aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.

The disclosure provides a FRET-based protein interaction assay that is capable of determining the dissociation constant for interactions between two proteins even if protein contaminants are present.

An apparatus for ligand binding assays includes an incubator that incubates a plurality of beads with a sample of interest wherein each of the plurality of beads comprises a tag of predetermined mass and a bait molecule. A washer washes the incubated beads so that weakly bound molecules are removed while strongly bound molecules are retained. A sample plate loader loads the washed beads into the sample plate such that respective ones of the plurality of beads are loaded into respective ones of the plurality of well. A sprayer deposits matrix assisted laser desorption ionization (MALDI) matrix material on the surface of the sample plate so that each of the plurality of beads is exposed to MALDI matrix material. A MALDI-TOF mass spectrometer receives the sample plate and performs mass spectrometry on samples in the plurality of wells. A computer executes an algorithm that analyzes the mass spectra.

Disclosed are methods of identifying binding moieties that recognize antigens displayed on cells, such as membrane proteins or recombinant proteins that display eptiopes on the surface of cells. Binding moieties capable of binding membrane proteins can be difficult to obtain because these proteins can depend on their native environments for structural integrity. In some methods scFv phage display libraries are panned against whole cells expressing a membrane protein in an emulsion. Certain methods further permit discrimination of binding moieties according to their affinity or avidity for a target. This approach allows rapid identification of cell surface epitope specific antibodies for research, diagnostics, and immunotherapeutics.

The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides methods and compositions for phage microarray profiling of cancer (e.g., prostate, lung, or breast cancer). The present invention further provides novel markers useful for the diagnosis, characterization, and treatment of cancers.

The present application provides arrays for use in immunosignaturing and quality control of such arrays. Also disclosed are peptide arrays and uses thereof for diagnostics, therapeutics and research.

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.

It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Accordingly, these compounds can be used as modulators of TNF. A new assay for identifying compounds with this mechanism of action is also disclosed.

The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40.

The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.